Oslo, Norway, 19 October 2023 - Circio Holding ASA (OSE: CRNA) today announces
that an abstract describing its circular RNA technology has been accepted for
poster presentation at the 30th i European Society for Gene and Cell Therapy in
Brussels, Belgium.

The poster is scheduled for presentation 25-26 October 2023 and will be
available on Circio's website (https://www.circio.com/en/circvec-platform/)
after the presentation.

Poster      circVec, a versatile circular RNA vector cassette for enhanced and
title:      durable intra-cellular protein expression
Date and    Wednesday 25 October 2023, 17:00- 18:16 CEST and Thursday 26
time:       October 2023, 20:30-21:30 CEST
Location:   Brussels, Belgium
Poster      P803
number:
Presenter:  Thomas Birkballe Hansen, VP and Head of Research, Erik Digman
            Wiklund, CEO

About European Society of Gene and Cell Therapy

The European Society of Gene and Cell Therapy (ESGCT) promotes basic and
clinical research in gene therapy, cell therapy, and genetic vaccines by
facilitating education, the exchange of information and technology and by
serving as a professional adviser to stakeholder communities and regulatory
bodies in Europe.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel
circRNA medicines for rare disease, vaccines, and cancer. The proprietary
circVec technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA from DNA and viral vectors, which can be
deployed for many purposes. The circVec platform has demonstrated enhanced and
more durable protein expression than classic mRNA vector systems, and has the
potential to become the new gold-standard for DNA and virus-based therapeutics
in the future. The circRNA R&D activities are being conducted by the wholly
owned subsidiary Circio AB based at the Karolinska Institute in Stockholm,
Sweden.

In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver
mutations. TG01 is currently being tested in two clinical trials in RAS-mutated
pancreatic cancer and multiple myeloma in the USA and Norway. These studies are
being run through academic collaborative networks, supported by prestigious
research grants from Innovation Norway and the Norwegian Research Council,
creating read-outs and future optionality for the program at low cost to Circio.